The FDA’s Center for Tobacco Products (CTP) just released one of its clearest signals yet that the agency is attempting to modernize and accelerate the PMTA review process.  

And for manufacturers, retailers, and adult consumers watching the nicotine category closely, the announcement could mark a significant shift in how product applications are reviewed moving forward. 

In a statement released by Acting CTP Director Bret Koplow, the agency outlined several new initiatives designed to improve efficiency, reduce delays, and streamline portions of the review process for nicotine pouch and ENDS applications.  

 

The FDA Says the PMTA Backlog Has Shrunk Dramatically 

 

One of the biggest takeaways from the announcement is the FDA’s claim that it reduced the PMTA backlog by approximately 70% during 2025.  

According to the agency: 

• There is no longer a waiting queue for applications pending Acceptance Review  
• PMTAs can now move into the first phase of review almost immediately after submission  
• Applicants no longer face waiting months or years simply to learn whether an application is complete enough to proceed  

That represents a major departure from the delays that defined the earlier years of the PMTA process. 

 

Filing Review Is Also Being Accelerated 

 

The FDA says it is now implementing new efficiencies during the Filing Review phase — the stage where regulators determine whether an application contains enough information to undergo substantive scientific review.  

According to the agency, these efficiencies have already been used for: 

• Nicotine pouch products  
• Electronic nicotine delivery systems (ENDS)  

For companies attempting to navigate the regulatory process, faster filing review could reduce uncertainty and improve planning timelines significantly. 

 

Supplemental PMTAs May Become Much Easier 

 

One of the more important developments involves the FDA’s plans for supplemental PMTAs. 

The agency says it is working on a process that would allow expedited review for certain modifications to already authorized products.  

Examples could include: 

• Improvements to electronics technology  
• Minor product modifications  
• Changes that do not fundamentally alter the product’s public health profile  

Historically, even relatively small product changes could create major regulatory burdens. If implemented effectively, this could make innovation far more realistic for companies operating within the legal market. 

 

The Nicotine Pouch Pilot Program Is Expanding 

 

The FDA also highlighted what it describes as the success of its nicotine pouch PMTA pilot program.  

According to CTP: 

• The first nicotine pouch authorizations under the pilot were issued just three months after scientific review began  
• FDA used real-time communication with applicants to request additional information faster  
• The pilot demonstrated that review timelines can move more efficiently while still maintaining scientific review standards  

The agency now says it plans to apply lessons learned from the pilot program to nicotine pouch PMTA reviews more broadly. 

 

Real-Time Communication Could Change the Process 

 

One of the more overlooked details in the announcement may actually be one of the most important. 

FDA says it has begun using more direct communication with applicants during scientific review to identify missing information earlier in the process.  

That matters because many companies have long criticized the PMTA process for being overly rigid, opaque, and slow-moving. 

More active communication between regulators and applicants could: 

• Reduce unnecessary delays  
• Improve application quality  
• Prevent avoidable denials  
• Create a more workable regulatory framework overall  

 

What This Means for the Industry 

 

The FDA is not eliminating PMTA requirements. 

Products still must undergo scientific review, and authorization standards still apply. 

But the tone of this announcement feels noticeably different from prior years. 

Instead of focusing primarily on enforcement and denials, the agency is now openly discussing: 

• Efficiency  
• Streamlining  
• Faster timelines  
• Innovation  
• Product modifications  
• Communication with applicants  

For an industry that has spent years dealing with uncertainty and shifting standards, that change in tone alone is significant. 

 

What Adult Consumers May Notice 

 

If these efforts continue successfully, consumers could eventually see: 

• Faster introduction of authorized nicotine pouch products  
• More innovation within authorized categories  
• Updated product technologies reaching the market sooner  
• A more stable legal marketplace overall  

That does not mean immediate changes overnight. 

But it does suggest the FDA may finally be recognizing that an endlessly delayed review system benefits nobody — not regulators, not responsible companies, and not adult consumers. 

 

Final Thoughts 

 

The PMTA process remains one of the most complicated regulatory systems in modern consumer products. 

But the FDA’s latest statements suggest the agency may finally be moving toward a more practical and efficient review framework — especially for nicotine pouches and potentially other reduced-risk nicotine products. 

Whether these promised improvements lead to meaningful long-term reform remains to be seen. 

But for the first time in a while, the FDA is talking less about bottlenecks and more about solutions.